Loading
Latest filing published 01 Oct 2026 for Xenon Pharmaceuticals Inc., €347k. Read the official filing
No signal scores available.
Thomas Patrick Kelly is a declared insider of Xenon Pharmaceuticals Inc., with filings sourced from SEC (Form 4). In total, 3 filings cover trades dated from 15 October 2025 to 30 September 2026.
Every open-market trade on record is a purchase: 1 purchase worth €347k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and no sales.
The newest entry dates from 1 October 2026: an open-market purchase of €347k, in Xenon Pharmaceuticals Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations